Spectrum Pharmaceuticals


Spectrum Pharmaceuticals, Inc. (SPPI) More Than Doubles Its Positive Responses Goal with Slam Dunk Updated Phase II Trial; H.C. Wainwright Chimes In

Edward White sees positive road ahead after SPPI’s compelling cancer asset hits ORR of 73% in Exon 20.

Investors Race to Buy Spectrum Pharmaceuticals, Inc. (SPPI) Shares; Here’s Why

Spectrum Pharmaceuticals, Inc.(NASDAQ:SPPI) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 50% upturn.

H.C. Wainwright Remains Positive On Spectrum Pharmaceuticals Following Unfavorable Patent Ruling

In a research report released Monday, H.C.

H.C. Wainwright Reiterates Buy On Spectrum Pharma Following 3Q14 Results

In a research note issued today, H.C.

Roth Capital Reiterates Buy On Spectrum Following 3Q14 Results

In a research report sent to investors today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Spectrum Pharmaceuticals (NASDAQ:SPPI) with a …

Roth Capital Reiterates Buy On Spectrum On The Back Of License Agreement With CASI

In a research report issued Friday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Spectrum Pharmaceuticals (NASDAQ:SPPI) with a $15 price target, following …

H.C. Wainwright Reiterates Buy On Spectrum On The Heels Of Phase 3 Plans For SPI-2012

In a research report issued today, H.C.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts